rivaxel 4.6mg/24hrs transdermal patches
sk chemicals co . ltd, korea - rivastigmine - transdermal patch - 9 mg
rivaxel 9.5mg/24hrs transdermal patches
sk chemicals co . ltd, korea - rivastigmine - transdermal patch - 18 mg
rivaxel 13.3mg/24hrs transdermal patches
sk chemicals co . ltd, korea - rivastigmine - transdermal patch - 27 mg
bupredermal buprenorphine 40 micrograms/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 40 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - bupredermal patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. bupredermal patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. bupredermal patches are not indicated as an as-needed (prn) analgesia.
bupredermal buprenorphine 30 micrograms/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 30 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - bupredermal patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. bupredermal patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. bupredermal patches are not indicated as an as-needed (prn) analgesia.
bupredermal buprenorphine 25 micrograms/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 25 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - bupredermal patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. bupredermal patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. bupredermal patches are not indicated as an as-needed (prn) analgesia.
bupredermal buprenorphine 20 micrograms/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; povidone; levulinic acid; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane - bupredermal patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. bupredermal patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. bupredermal patches are not indicated as an as-needed (prn) analgesia.
bupredermal buprenorphine 15 micrograms/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - bupredermal patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. bupredermal patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. bupredermal patches are not indicated as an as-needed (prn) analgesia.
bupredermal buprenorphine 10 micrograms/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; povidone; levulinic acid; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - bupredermal patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. bupredermal patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. bupredermal patches are not indicated as an as-needed (prn) analgesia.
bupredermal buprenorphine 5 micrograms/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - bupredermal patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. bupredermal patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. bupredermal patches are not indicated as an as-needed (prn) analgesia.